Holen Sie sich die Stockscreener-App
1.37
8.73%
0.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SCYX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.26
Offen:
$1.24
24-Stunden-Volumen:
232.58K
Relative Volume:
1.52
Marktkapitalisierung:
$47.81M
Einnahmen:
$135.87M
Nettoeinkommen (Verlust:
$72.20M
KGV:
1.631
EPS:
0.84
Netto-Cashflow:
$45.09M
1W Leistung:
+16.10%
1M Leistung:
-6.80%
6M Leistung:
-41.70%
1J Leistung:
-16.97%
1-Tages-Spanne:
$1.24
$1.375
1-Wochen-Bereich:
$1.1598
$1.375
52-Wochen-Spanne:
$1.15
$3.07
Scynexis Inc Stock (SCYX) Company Profile
Firmenname
Scynexis Inc
Sektor
Telefon
201-884-5485
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Vergleichen Sie SCYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
1.37 | 47.81M | 135.87M | 72.20M | 45.09M | 0.84 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-22 | Eingeleitet | Guggenheim | Buy |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Hochstufung | Needham | Hold → Buy |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-10 | Eingeleitet | ROTH Capital | Buy |
| 2017-05-09 | Herabstufung | Needham | Buy → Hold |
| 2017-03-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-07 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2016-08-17 | Eingeleitet | Guggenheim | Buy |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-08-09 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Eingeleitet | Brean Capital | Buy |
| 2015-12-29 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-06-10 | Eingeleitet | Needham | Buy |
| 2014-05-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2014-05-29 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Scynexis Inc Aktie (SCYX) Neueste Nachrichten
Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com
Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com
SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com
SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle
SCYNEXIS announces new $50 million equity sales agreement - Investing.com India
SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. In - GuruFocus.com
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving AverageShould You Sell? - MarketBeat
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - The Manila Times
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82 - MarketBeat
CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha
Potential Price Increase for Synopsys, Inc. (SNPS) After Recent Insider Activity - Knox Daily
Scynexis CEO acquires $27,400 in company stock By Investing.com - Investing.com Canada
Syncona Advances Share Buyback, Bolsters Treasury Shares - TipRanks
Xero buys South African firm for $115m in 'departure' - New Zealand Herald
SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Buys 20,000 Shares - MarketBeat
Scynexis CEO acquires $27,400 in company stock - Investing.com
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Better than expected profits forecast for security tech company - The Business Desk
Synopsys Inc. stock rises Friday, still underperforms market - MarketWatch
SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average of $1.83 - MarketBeat
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook - TipRanks
SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200-Day Moving Average of $1.84 - MarketBeat
SCYX stock touches 52-week low at $1.35 amid market challenges - Investing.com
Financial Fitness Check: Examining Scynexis Inc (SCYX)’s Key Ratios - The Dwinnex
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
SCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to Sell - Defense World
SCYNEXIS (NASDAQ:SCYX) Downgraded to "Sell" at StockNews.com - MarketBeat
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Scynexis: Q2 Earnings Snapshot - San Antonio Express-News
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt? - Simply Wall St
Finanzdaten der Scynexis Inc-Aktie (SCYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):